Introduction The microbiome is one of the hottest areas in biotechnology, as countless studies have linked its composition and activity with human disease1,2, especially in illnesses of poorly understood mechanisms, with high medical unmet needs. […]
The global public health community is responding to a rapidly evolving pandemic of respiratory disease caused by a novel coronavirus that was first detected in China. The virus has been named “SARS-CoV-2” and the disease […]
Today, DuPont Nutrition & Biosciences (DuPont) announced a second collaboration with the APC Microbiome Ireland SFI Research Center (APC), a pioneer in the field of microbiome science, which focuses on microbes that live in and […]
The Food and Drug Administration (FDA) is informing health care providers and patients of the potential risk of serious or life-threatening infections with the use of fecal microbiota for transplantation (FMT). The agency is now aware […]
Introduction With every article of the Microbiome Times, one sees the therapeutic microbiome industry edging ever-closer to full commercialisation of their products. Understandably, much of the focus has been on the challenging process of demonstrating […]
A new paper published today in Nature Communications introduces VIRGO, the first comprehensive non-redundant gene catalog of the human vaginal microbiome. Powered by the largest integrated data set of vaginal metagenomes and metatranscriptomes to date, […]
SkinBioTherapeutics, a life science company focused on skin health, announces that its wholly owned subsidiary, AxisBiotix Limited, has signed a development agreement with Winclove Probiotics B.V., (“Winclove”), a specialist in the research, development and manufacture of […]
DuPont Nutrition & Biosciences (DuPont) today announced a collaboration with the MRM Health NV (MRM Health), a biopharmaceutical company, focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health […]
Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to protect the intestinal microbiota from the damaging effects of antibiotics, today announced positive top-line results from a Phase 2 clinical trial ‘SHIELD’ evaluatingDAV132 in patients […]
Many different chronic diseases have been associated with distinct gut microbiome ‘signatures’, but what has proved challenging to date is the translation of the compositional and functional microbiome differences into novel diagnostics and therapeutics. Moving […]
Rebiotix, a Ferring company, announced today that it has completed enrollment of the pivotal Phase 3 clinical trial for RBX2660, an investigational therapy aimed at breaking the cycle of recurrent Clostridioides difficile (C. diff) infection, […]